British journal of haematology · 2021
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Begna Kebede H, Kittur Jaya, Yui Jennifer, Gangat Naseema, Patnaik Mrinal M, Al-Kali Aref, Elliott Michelle A, Hogan William J, Litzow Mark R, Hook Christopher C, Wolanskyj Alexandra P, Howard Matthew T, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh D, Tefferi Ayalew
Аннотация
Institutional database search (1999-2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment-induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.
Предметные рубрики MeSH
Abnormal KaryotypeAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone MarrowFemaleGastrointestinal TractHematopoietic Stem Cell TransplantationHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryNeoplastic Cells, CirculatingRecurrenceSarcoma, MyeloidSkinTransplantation, AutologousTreatment OutcomeYoung Adult